作者
Bernhard Scheiner, Katharina Pomej, Martha M Kirstein, Florian Hucke, Fabian Finkelmeier, Oliver Waidmann, Vera Himmelsbach, Kornelius Schulze, Johann von Felden, Thorben W Fründt, Marc Stadler, Harald Heinzl, Kateryna Shmanko, Stephan Spahn, Pompilia Radu, Alexander R Siebenhüner, Joachim C Mertens, Nuh N Rahbari, Fabian Kütting, Dirk-Thomas Waldschmidt, Matthias P Ebert, Andreas Teufel, Sara De Dosso, David J Pinato, Tiziana Pressiani, Tobias Meischl, Lorenz Balcar, Christian Müller, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Nicola Personeni, Lorenza Rimassa, Michael Bitzer, Jörg Trojan, Arndt Weinmann, Henning Wege, Jean-François Dufour, Markus Peck-Radosavljevic, Arndt Vogel, Matthias Pinter
发表日期
2022/2/1
期刊
Journal of hepatology
卷号
76
期号
2
页码范围
353-363
出版商
Elsevier
简介
Background & Aims
Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need.
Methods
Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patients treated with sorafenib (n = 204).
Results
Baseline serum alpha-fetoprotein ≥100 ng/ml (hazard ratio [HR] 1.7; p = 0.007) and C-reactive protein ≥1 mg/dl (HR, 1.7; p = 0.007 …
学术搜索中的文章
B Scheiner, K Pomej, MM Kirstein, F Hucke… - Journal of hepatology, 2022